Takeda completes share repurchase program

Takeda Pharmaceutical Company Limited (TSE:4502) announced the completion of its share repurchase program, initiated under Article 459, paragraph 1 of the Companies Act of Japan, based on the resolution of the Board of Directors' meeting held on January 30, 2025. The company acquired a total of 23,367,100 shares of its common stock at a total cost of JPY 99,955,865,500. During the most recent period, from April 1, 2025, to April 21, 2025, Takeda repurchased 11,823,500 shares at a cost of JPY 49,977,956,800. The repurchases were executed through open-market transactions via a trust bank. This completes the share repurchase program authorized on January 30, 2025, which permitted the acquisition of up to 28.5 million shares, equivalent to 1.80% of outstanding shares (excluding treasury shares) for a total cost of up to JPY 100 billion, between February 17, 2025 and May 31, 2025.